Airway Basal Stem Cells

Phase 1Biologic

RRegend Therapeutics

Airway Basal Stem Cells is one of 29 biologic programs targeting Bronchiolitis Obliterans. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bronchiolitis ObliteransActive, not recruiting

Bronchiolitis ObliteransPhase 1

Active, not recruiting

Competition

Competitive Landscape

33 competitors in Bronchiolitis Obliterans

#DrugCompanyPhaseTrials

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

5 2

Neoral

Biaxin

Singulair

2 5

Velcade

SShilpa Grover, MD, MPH

Aztreonam Lysine

1 7

Esbriet

LLegacy Health System

Foradil

Pulmicort

Simulect

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Bronchiolitis Obliterans

NCT07239895

Clinical

Trials by Indication[1]

Bronchiolitis Obliterans1 trial

Treatment of Pediatric Bronchiolitis Obliterans by Airway Basal Stem Cells

Recruiting·RRegend Therapeutics·Phase 1·NCT07239895·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Airway Basal Stem Cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Airway Basal Stem Cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Airway Basal Stem Cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regend Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: RRegend Therapeutics

Airway Basal Stem Cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Bronchiolitis Obliterans1 trial

References

Drug Info

Quick Facts

Related News